Targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Pharmaceutics

• Publication date

  2010-11-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1021/mp100259aPMID 20958081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Role of the Intestinal Lymphatics in the Absorption of Two Highly Lipophilic Cholesterol Ester Transfer Protein Inhibitors (CP524,515 and CP532,623)

  2010cited by this paper
• The Mechanism of Lymphatic Access of Two Cholesteryl Ester Transfer Protein Inhibitors (CP524,515 and CP532,623) and Evaluation of Their Impact on Lymph Lipoprotein Profiles

  2010cited by this paper
• The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride‐rich lipoproteins: in‐silico prediction of uptake by chylomicrons

  2009cited by this paper
• Materials engineering for immunomodulation

  2009cited by this paper
• Adverse drug reactions to antiretroviral medication.

  2009cited by this paper
• CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways.

  2008cited by this paper
• Chronic HCV-related autoimmunity: a consequence of viral persistence and lymphotropism.

  2007cited by this paper
• Immune control by endocannabinoids - new mechanisms of neuroprotection?

  2007cited by this paper
• Nanosystems for simultaneous imaging and drug delivery to T cells

  2007cited by this paper
• Exploiting lymphatic transport and complement activation in nanoparticle vaccines

  2007cited by this paper
• Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update

  2007cited by this paper
• CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents.

  2007cited by this paper
• Pathogenesis of HIV in the gastrointestinal tract

  2007cited by this paper
• Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs

  2007cited by this paper
• Receptor (SLAM [CD150]) Recognition and the V Protein Sustain Swift Lymphocyte-Based Invasion of Mucosal Tissue and Lymphatic Organs by a Morbillivirus

  2006cited by this paper
• In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.

  2006cited by this paper
• Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection

  2006cited by this paper
• AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

  2006cited by this paper
• The Lymph Lipid Precursor Pool Is a Key Determinant of Intestinal Lymphatic Drug Transport

  2006cited by this paper
• Immunopathogenesis of acute AIDS virus infection.

  2006cited by this paper
• Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells.

  2006cited by this paper
• Normal Structure, Function, and Histology of Mucosa-Associated Lymphoid Tissue

  2006cited by this paper
• Bile Increases Intestinal Lymphatic Drug Transport in the Fasted Rat

  2005cited by this paper
• Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.

  2005cited by this paper
• Lymphocyte homing to the gut: attraction, adhesion, and commitment

  2005cited by this paper
• Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability.

  2005cited by this paper
• Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers.

  2005cited by this paper
• Selectins-an emerging target for drug delivery.

  2004cited by this paper
• Drug Solubilization Behavior During in Vitro Digestion of Simple Triglyceride Lipid Solution Formulations

  2004cited by this paper
• Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid‐type CB2 receptor

  2003cited by this paper
• Gastrointestinal tuberculosis

  2003cited by this paper
• Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis

  2003cited by this paper
• A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum

  2003cited by this paper
• A small-volume technique for simultaneous immunophenotyping and apoptosis detection in rat whole blood by four-color flow cytometry.

  2002cited by this paper
• Binding and Internalization of an LFA-1-Derived Cyclic Peptide by ICAM Receptors on Activated Lymphocyte: A Potential Ligand for Drug Targeting to ICAM-1-Expressing Cells

  2001cited by this paper
• A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine.

  2001cited by this paper
• Solubilization of rapamycin.

  2001cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Treatment of transplant rejection: are the traditional immunosuppressants good enough?

  2001cited by this paper
• Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats.

  2001cited by this paper
• Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats.

  2000cited by this paper
• Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

  2000cited by this paper
• Influence of enteral diets supplemented with key nutrients on lymphocyte subpopulations in Peyer's patches of endotoxin-boostered mice.

  2000cited by this paper
• Enhanced lymphocyte interaction in postcapillary venules of Peyer's patches during fat absorption in rats.

  1997cited by this paper
• Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion.

  1996cited by this paper
• Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: effect of lipid class and lipid vehicle dispersion.

  1996cited by this paper
• Triacylglycerol metabolism by lymphocytes and the effect of triacylglycerols on lymphocyte proliferation.

  1994cited by this paper
• Gut intraepithelial T lymphocytes.

  1993cited by this paper
• Increased proliferative response of lymphocytes from intestinal lymph during long chain fatty acid absorption.

  1993cited by this paper
• Promotion of lymphocyte growth by high density lipoproteins (HDL). Physiological significance of the HDL binding site.

  1989cited by this paper
• Lipoproteins may provide fatty acids necessary for human lymphocyte proliferation by both low density lipoprotein receptor-dependent and -independent mechanisms.

  1989cited by this paper
• Increased lymphocyte transport by lipid absorption in rat mesenteric lymphatics.

  1987cited by this paper
• Enhanced Selective Lymphatic Delivery of Cyclosporin A by Solubilizers and Intensified Immunosuppressive Activity Against Mice Skin Allograft

  1986cited by this paper
• Macrophage uptake of a lipoprotein-sequestered toxicant: a potential route of immunotoxicity.

  1986cited by this paper
• Promotion of human T lymphocyte activation and proliferation by fatty acids in low density and high density lipoproteins.

  1986cited by this paper
• Promotion of the selective lymphatic delivery of cyclosporin A by lipid-surfactant mixed micelles.

  1985cited by this paper
• Intestinal lymphatic absorption of cyclosporin A following oral administration in an olive oil solution in rats.

  1983cited by this paper
• Binding of benzo[a]pyrene and intracellular transport of a bound electrophilic benzo[a]pyrene metabolite by lipoproteins.

  1982cited by this paper
• The entry of foreign compounds into the thoracic duct lymph of the rat.

  1974cited by this paper

• Primary Small Intestinal Epithelia Are Physiological Alternatives to the Caco-2 Lymphatic Transport Model.

  2025cites this paper
• Predicting lymphatic transport potential using graph transformer based on limited historical data from in vivo studies.

  2025cites this paper
• Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

  2024cites this paper
• Functionalization and magnetonavigation of T-lymphocytes functionalized via nanocomposite capsules targeting with electromagnetic tweezers.

  2024cites this paper
• Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy

  2023cites this paper
• Development and application of a novel cervical lymph collection method to assess lymphatic transport in rats

  2023cites this paper
• Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis.

  2023cites this paper
• Obesity-associated mesenteric lymph leakage impairs the trafficking of lipids, lipophilic drugs and antigens from the intestine to mesenteric lymph nodes.

  2022cites this paper
• Drug delivery to the intestinal lymph by oral formulations

  2022influential citation
• Sonoporation of Immune Cells: Heterogeneous Impact on Lymphocytes, Monocytes and Granulocytes.

  2022cites this paper
• A lymphatic-absorbed multi-targeted kinase inhibitor for myelofibrosis therapy

  2022cites this paper
• Intra-articular injection of biologic anti-rheumatic drugs enhances local exposure to the joint-draining lymphatics.

  2022cites this paper
• Unleashing cell-penetrating peptide applications for immunotherapy.

  2022cites this paper
• A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling

  2021cites this paper
• Targeted delivery of mycophenolic acid to the mesenteric lymph node using a triglyceride mimetic prodrug approach enhances gut-specific immunomodulation in mice.

  2021cites this paper
• Lymphatic Transport of Drugs after Intestinal Absorption: Impact of Drug Formulation and Physicochemical Properties

  2020cites this paper
• Design of novel tacrolimus formulations with chemically synthesized oils for oral lymphatic delivery

  2020cites this paper
• Intestinal lymphatic transport study of antitumor lead compound T-OA with liposomes.

  2020cites this paper
• Lymph-directed immunotherapy - Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer.

  2020cites this paper
• Promoting intestinal lymphatic transport targets a liver‐X receptor (LXR) agonist (WAY‐252,623) to lymphocytes and enhances immunomodulation

  2019cites this paper
• Cannabinoids and inflammation: Implications for People Living with HIV.

  2019cites this paper
• Therapeutic delivery to the peritoneal lymphatics: current understanding, potential treatment benefits and future prospects.

  2019cites this paper
• The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

  2019cites this paper
• BSA-coated fluorescent organic-inorganic hybrid silica nanoparticles: preparation and drug delivery

  2017cites this paper
• Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation

  2017cites this paper
• Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.

  2016cites this paper
• Metabolic regulation of immune responses: therapeutic opportunities.

  2016cites this paper
• Targeting Immunomodulatory Agents to the Gut-Associated Lymphoid Tissue

  2016cites this paper
• Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug.

  2016cites this paper
• Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability.

  2016cites this paper
• A trial for the design and optimization of pH-sensitive microparticles for intestinal delivery of cinnarizine

  2016cites this paper
• Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats

  2016cites this paper
• Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs.

  2016cites this paper
• Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies

  2015cites this paper
• Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement

  2015cites this paper
• From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

  2015cites this paper
• ROLE OF LIPID-BASED DELIVERY SYSTEMS IN THE BIOLOGICAL FATE OF LIPOPHILIC NUTRACEUTICALS AND INORGANIC NANO-PARTICLES IN THE GASTROINTESTINAL TRACT

  2015cites this paper
• The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport.

  2015cites this paper
• Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.

  2015cites this paper
• Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug

  2015cites this paper
• Self-Emulsifying Drug Delivery System for Enhancing Bioavailability and Lymphatic Delivery of Tacrolimus.

  2015cites this paper
• Recent approaches of lipid-based delivery system for lymphatic targeting via oral route

  2014cites this paper
• Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.

  2014cites this paper
• Harnessing lipid absorption pathways to target the lymphatic system.

  2014cites this paper
• Nano-sized drug delivery systems for lymphatic delivery.

  2014cites this paper
• The Role of Lymphatic Transport on the Systemic Bioavailability of the Bcl-2 Protein Family Inhibitors Navitoclax (ABT-263) and ABT-199

  2014cites this paper
• Lactosylated poly(ethylene oxide)–poly(propylene oxide) block copolymers for potential active targeting: synthesis and physicochemical and self-aggregation characterization

  2013cites this paper
• Comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies to target a model immunomodulator to the lymphatic system

  2013cites this paper
• Enhanced lymphatic transport of bioactive lipids: cell culture study of polymethoxyflavone incorporation into chylomicrons.

  2013cites this paper
• A Mouse Model to Evaluate the Impact of Species, Sex, and Lipid Load on Lymphatic Drug Transport

  2013cites this paper
• The impact of lymphatic transport on the systemic disposition of lipophilic drugs.

  2013cites this paper
• Intestinal transport as a potential determinant of drug bioavailability.

  2013cites this paper
• Recent developments in oral lipid-based drug delivery

  2013cites this paper
• DMD055053 207..212

  2013influential citation
• Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.

  2012cites this paper
• The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons.

  2012cites this paper
• Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.

  2012cites this paper
• Correction to "targeted drug delivery to lymphocytes: a route to site-specific immunomodulation?".

  2011cites this paper